Loading...

Home
ETF
BTAI

BTAI

-

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

Overview Technical News

Most Trusted AI Platform for Winning Trades

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

Home
Contact
About Us
Press
Privacy
Terms of Service
Service Terms of Use

Resources

Blog
Tutorial
Help Center
Affiliate Program

Markets

Market Analysis
Crypto
Featured Screeners
AI Earnings Calendar
Market Movers
Stock Monitor
Economic Calendar
All US Stocks
All Cryptos

Tools

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Features

QuantAI Alpha Pick
SwingMax Portfolio
Swing Trading
AI Stock Picker
Whales Auto Tracker
Daytrading Center
Patterns Detection
AI Screener
Financial AI Agent
Backtesting Playground
AI Earnings Prediction
Stock Monitor
Technical Analysis

News

Overview
Top News
Daily Market Brief
Earnings Analysis
Newswire
Stock News
Crypto News
Institution News
Congress News
Monitor News

Compare

TradingView
SeekingAlpha

BTAI News

BioXcel Therapeutics Q4 Earnings Beat Expectations

4d agoseekingalpha

BioXcel Submits sNDA for IGALMI® in At-Home Treatment

3d agoNewsfilter

BioXcel Therapeutics Enters Securities Purchase Agreement for $8 Million Offering

Mar 10 2026Newsfilter

BioXcel Therapeutics Shares Decline Despite Positive Drug Development News

Mar 06 2026Benzinga

BIOXCEL THERAPEUTICS STOCK INCREASES 2.7% FOLLOWING POSITIVE RESULTS FROM MID-STAGE TRIAL OF EXPERIMENTAL OPIOID WITHDRAWAL TREATMENT

Mar 05 2026moomoo

BioXcel Therapeutics Reports Positive Phase 2 Results for Opioid Withdrawal Treatment

Mar 05 2026Benzinga

BioXcel Therapeutics Reports Positive Phase 2 Trial Results for Opioid Withdrawal Treatment

Mar 05 2026stocktwits

Halper Sadeh Investigates BioXcel Therapeutics for Potential Breach of Fiduciary Duties

Jan 15 2026Businesswire

BioXcel Seeks FDA Approval for At-Home Use of IGALMI® in Agitation Treatment

Jan 09 2026Newsfilter

BioXcel Seeks FDA Approval for At-Home Use of IGALMI in Agitation Treatment

Jan 07 2026NASDAQ.COM

BioXcel Therapeutics Hosts Virtual Roundtable on Self-Administered Treatment Opportunities

Dec 03 2025Globenewswire

BioXcel Hosts Roundtable on Self-Administered Treatments for 77M Agitation Episodes

Dec 03 2025Newsfilter

BioXcel Therapeutics to Celebrate Major Neuroscience Achievement by Ringing Nasdaq Closing Bell on October 14

Oct 13 2025Newsfilter

BioXcel Meets Nasdaq Listing Requirements Again

Sep 18 2025SeekingAlpha

BioXcel Medication Eases Home Agitation in Patients with Schizophrenia and Bipolar Disorder

Sep 10 2025Benzinga

BioXcel Therapeutics Announces Encouraging Preliminary Efficacy Results from SERENITY At-Home Phase 3 Safety Trial for Agitation Linked to Bipolar Disorders or Schizophrenia

Sep 10 2025Newsfilter